Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab

Eur J Dermatol. 2019 Aug 1;29(4):448-449. doi: 10.1684/ejd.2019.3614.

Authors

Franziska Grän¹, Matthias Goebeler¹, Anja Gesierich¹

Affiliation

¹ Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany.

PMID: 31625927
DOI: 10.1684/ejd.2019.3614

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Cell Cycle Checkpoints / drug effects
Humans
Male
Middle Aged
Nivolumab / adverse effects*
Pemphigoid, Bullous / chemically induced*

Substances

Antineoplastic Agents, Immunological
Nivolumab